<DOC>
	<DOCNO>NCT02630901</DOCNO>
	<brief_summary>This multiple ascend dose study determine safety , tolerability , pharmacokinetics immunogenicity PRX003 approximately 56 patient Psoriasis .</brief_summary>
	<brief_title>Multiple Ascending Dose Study PRX003 Subjects With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Male female , 18 80 year age ( inclusive ) , body weight range ≥ 45 kg ( 99 lb ) ≤ 120 kg ( 264 lb ) body mass index ( BMI ) 18 35 kg/m2 2 . Provide write informed consent 3 . PASI score ≥12 4 . Plaque psoriasis cover ≥10 % BSA 5. sPGA score 3 4 6 . Able perform protocolspecified assessment comply study visit schedule 7 . Female subject postmenopausal surgically sterile must use physician approve contraception least 60 day prior Baseline ( Day 1/Visit 2 ) 12 week follow last study drug administration . Unless least 2 year postmenopausal surgically sterile , woman must pregnancy test follicle stimulate hormone ( FSH ) &gt; 40 IU/L estradiol &lt; 20 pg/mL ( unless hormonereplacement therapy ) . Women childbearing potential must non lactate negative serum pregnancy test ( beta human chorionic gonadotropin [ β HCG ] ) Screening ( Visit 1 ) . 8 . If male , must surgically sterile must agree use physicianapproved contraception Baseline ( Day 1/Visit 2 ) 12 week follow last study drug administration 1 . Presents psoriasis predominantly guttate , erythrodermic , inverse , pustular palmoplantar , unstable form psoriasis 2 . Receipt follow within specified time frame prior Baseline ( Day 1/Visit 2 ) : Topical psoriasis treatment ( lowpotency topical corticosteroid emollient , permit study ) within 2 week Systemic ( nonbiologic ) psoriasis treatment within 4 week 5 halflives ( whichever longer ) Biologic psoriasis treatment within 12 week 5 halflives ( whichever longer ) Drugs appear strong causal relationship psoriasis ( e.g. , betablockers lithium ) within 4 week 5 halflives ( whichever longer ) Phototherapy within 4 week 3 . Participation recreational sunbathing use sunbed ( e.g. , tan salon ) within 7 day prior Baseline ( Day 1 ) 4 . Any major medical illness unstable medical condition , opinion Investigator Sponsor , may interfere subject 's ability comply study procedure abide study restriction , ability interpret safety data , include , limited : Within 5 year Screening ( Visit 1 ) History cancer exception fully excise nonmelanoma skin cancer History stroke History epilepsy seizure disorder febrile seizures child , seizure loss consciousness History active autoimmune disease ( psoriasis PsA ) Within 2 year Screening ( Visit 1 ) Myocardial infarction Clinically significant cardiovascular disease include follow : unstable angina , decompensated congestive heart failure , clinically significant arrhythmias Vascular disease , include , limited , blood clotting disorder , atherosclerosis , aneurysms , renal artery disease 5 . Hypotension ( systolic blood pressure [ BP ] ≤85 millimeter mercury [ mmHg ] ) Baseline ( Day 1/Visit 2 ) predose know history documentation hypotension one occasion within 3 month prior Baseline ( Day 1/Visit 2 ) 6 . Uncontrolled hypertension indicate rest systolic BP ≥150 mmHg diastolic BP ≥95 mmHg Screening ( Visit 1 ) Baseline ( Day 1/Visit 2 ) predose know history documentation uncontrolled hypertension one occasion within 3 month prior Baseline ( Day 1/Visit 2 ) 7 . Clinically significant systemic infection ( e.g. , chronic acute infection , urinary tract infection , upper respiratory infection ) within 30 day Baseline ( Day 1/ Visit 2 ) , history presence recurrent chronic infection ( e.g. , viral infection [ include hepatitis B C , human immunodeficiency virus ( HIV ) ] , bacterial infection , systemic fungal infection , syphilis ) 8 . History inflammatory bowel disease 9 . Any current psychiatric diagnosis accord Diagnostic Statistical Manual Mental Disorders IV Text Revision ( DSMIVTR ) may interfere subject 's ability perform study assessment ( e.g. , alcohol drugrelated abuse alcohol dependence , alcohol drugrelated dementia , major depression , developmental disability , schizophrenia , bipolar disorder ) . Note : Subjects adequately control depression least 6 month exclude ; however , suicidal ideation attempt time within past year exclusionary . 10 . A positive tuberculosis skin test ( TST ) positive interferongamma release assay ( IGRA ) Screening ( Visit 1 ) . Note : In event subject TST IGRA within 3 month Baseline ( Day 1/Visit 2 ) , need repeat screen previous result carry forward use study . Prior standard treatment latent tuberculosis prior exposure tuberculosis subsequent standard prophylactic treatment allow recent ( within ˂ 30 day ) negative chest Xray . 11 . Any following laboratory abnormality Screening ( Visit 1 ) : Total bilirubin ( unless attribute Gilbert 's syndrome ) &gt; 1.5 time upper limit normal ( × ULN ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 × ULN Serum creatinine &gt; 133 µmol/L ( 1.5 mg/dL ) Hemoglobin &lt; 11.5 g/dL male &lt; 10.0 g/dL female , absolute neutrophil count ˂1500/µL ( exception document history chronic benign neutropenia ) , platelet count &lt; 120,000/µL 12 . Use investigational product device participation drug research study within period 30 day ( 5 halflives drug , whichever long ) prior Screening ( Visit 1 ) ; investigational product drug research study relate psoriasis arthritis , duration extend 12 week ( 5 halflives drug , whichever long ) prior Screening ( Visit 1 ) 13 . Allergy component PRX003 histidine , sucrose polysorbate 20 14 . Receipt vaccine ( exception seasonal influenza ) within 30 day prior Screening ( Visit 1 ) 15 . Donation &gt; 500 mL blood within 3 month prior Screening ( Visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>